• トップ
• The announcement of initiation of Phase I clinical study for OTS167 (oral administration) in patients with Breast Cancer including Triple-Negative Breast Cancer at Weill Cornell Medicine

The announcement of initiation of Phase I clinical study for OTS167 (oral administration) in patients with Breast Cancer including Triple-Negative Breast Cancer at Weill Cornell Medicine